Alnylam Announces Five-Year HELIOS-B Data on AMVUTTRA

First Solar Shares Fall 4.9%, Worst Performer in S&P 500 First Solar shares fell 4.9% to $191.24 on Monday, making them the S&P 500’s worst performer as the index rose 2.1%. M impact | EQUITY | Nov 09, 2026, 06:47 PM UTC

US session market picture: S&P 500 +2.24%, Nasdaq 100 +3.03%; EUR/USD +0.58%, WTI -3.45%, NVDA leads volume US session market picture. US index futures: S and P futures is up 2.24 percent, Nasdaq futures is up 3.03 percent, Dow futures is up 2.14 percent and Russell futures is up 2.97 pe M impact | EQUITY | Nov 09, 2026, 06:30 PM UTC

Motorcar Parts of America Reports Quarterly Results Motorcar Parts of America reported results for the quarter ended September 30. M impact | EQUITY | Nov 09, 2026, 06:28 PM UTC

Warner Bros. Ousts James Gunn and Peter Safran as DC Studios Heads Warner Bros.'s new parent company has removed director James Gunn and producer Peter Safran from their leadership roles at DC Studios. L impact | EQUITY | Nov 09, 2026, 06:22 PM UTC

European Stocks Close Higher as Oil Prices Fall Sharply European markets ended Monday higher, supported by lower oil prices and easing bond yields. Rising precious metals prices lifted mining stocks, while rating upgrades also contribut M impact | EQUITY | Nov 09, 2026, 06:11 PM UTC

Merck Phase 2b Trial Reports MASH Resolution Rates of 56%–63% Merck said its Phase 2b trial met its primary endpoint. MASH resolution without worsening fibrosis at 52 weeks was 56%, 63% and 61% across efinopegdutide doses, versus 13% for plac M impact | EQUITY | Nov 09, 2026, 06:05 PM UTC

Alnylam Announces Five-Year HELIOS-B Data on AMVUTTRA

Related stories